Today, in Europe, PD-L1 expression evaluation on tumor cells by IHC with Tumor Proportional Score (TPS) is the only immune-checkpoint inhibitor positive predictive biomarker approved for NSCLC patients in first- and second-line treatment, in particular for pembrolizumab [6, 36]. This evidence concerns the gene CD274 and neoplasm.